TJM Labs says it raised $100M and serves 450 pharmacies

TJM Labs disclosed $100 million in funding, 450+ live pharmacies and two acquisitions as it pushes a pharmacy-native AI platform. The company says its agents now handle more than 500,000 tasks a day, signaling a move from pilot projects to enterprise infrastructure in pharmacy operations.

Why it matters: - TJM Labs is positioning pharmacy AI as operational infrastructure, not a pilot experiment. - The company says its software is reducing repetitive work that contributes to burnout and bottlenecks in pharmacy teams. - The platform is designed to help pharmacists and technicians spend more time on patient care.

What happened: - TJM Labs announced it has raised $100 million across three funding rounds in about six months. - The rounds included a $10 million Series A, a $15 million Series A-1 and a $75 million Series B led by Elephant, with participation from Arthur Ventures and Updata. - TJM Labs said it is now live in more than 450 pharmacies. - TJM Labs also said it completed two acquisitions, EncoreRx and Pharmesol. - The company said the acquisitions add automation and voice capabilities to one pharmacy-native platform.

The details: - TJM Labs builds AI agents that automate prescription intake, data entry, refills, prior authorization support and patient communication. - The agents work across the pharmacy systems teams already use. - The company said the platform processes more than 500,000 pharmacy tasks every day. - Jonathan Adly, founder and CEO, said the company was built by pharmacists and engineers working side by side. - Adly said he worked as a pharmacist for 15 years before founding TJM Labs. - TJM Labs uses a Dual-Expert Model™ that pairs pharmacists with AI engineers on deployments. - The model is meant to align automation with pharmacy workflows, operational complexity and pharmacist oversight. - TJM Labs said its AI agents do not require a rip-and-replace system overhaul. - The company has scaled across retail, specialty, compounding, long-term care, mail order, central fill and enterprise pharmacy settings. - TJM Labs said its customer base includes independent pharmacies and high-volume, multi-location operations. - One customer, Valor Compounding Pharmacy, said the platform helped the pharmacy leverage its existing tech stack and reduce manual work.

Between the lines: - TJM Labs is using funding, acquisitions and deployment scale to define a category that is still early and fragmented. - Elephant General Partner Jeremiah Daly framed the company as a production platform already operating inside hundreds of pharmacies. - The company’s message is that pharmacy AI is shifting from experimentation to infrastructure. - The acquisition strategy suggests TJM Labs wants to consolidate point solutions into one system.

What's next: - TJM Labs said it will continue expanding the pharmacy-native platform across more operational workflows. - The company is likely to push deeper into enterprise pharmacy environments as the market consolidates. - More pharmacies may adopt the platform as AI moves from testing to day-to-day operations.

The bottom line: - TJM Labs wants to be the default operating layer for pharmacy AI, and it is backing that claim with capital, acquisitions and live deployments.